Fleury H - Search Results

1

Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003.

Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Jørgensen LB, Pedersen C, van der Hoek L, Prins M, Balotta C, Longo B, Kücherer C, Poggensee G, Ortiz M, de Mendoza C, Gill J, Fleury H, Porter K; CASCADE Collaboration. Masquelier B, et al. Among authors: fleury h. J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):505-11. doi: 10.1097/01.qai.0000186361.42834.61. J Acquir Immune Defic Syndr. 2005. PMID: 16284524

2

Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.

Masquelier B, Pereira E, Peytavin G, Descamps D, Reynes J, Verdon R, Fleury H, Garraffo R, Chêne G, Raffi F, Brun-Vézinet F; APROCO/COPILOTE Study Group. Masquelier B, et al. Among authors: fleury h. J Clin Virol. 2005 May;33(1):75-8. doi: 10.1016/j.jcv.2004.11.012. J Clin Virol. 2005. PMID: 15797369 Clinical Trial.

3

Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load.

Bezemer D, de Ronde A, Prins M, Porter K, Gifford R, Pillay D, Masquelier B, Fleury H, Dabis F, Back N, Jurriaans S, van der Hoek L; CASCADE collaboration. Bezemer D, et al. Among authors: fleury h. Antivir Ther. 2006;11(2):173-8. Antivir Ther. 2006. PMID: 16640098

4

Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort.

Peuchant O, Capdepont S, Ragnaud JM, Aurillac-Lavignolle V, Thiébaut R, Fleury H, Masquelier B; ANRS CO3 Aquitaine Cohort. Peuchant O, et al. Among authors: fleury h. Antivir Ther. 2007;12(4):559-62. doi: 10.1177/135965350701200413. Antivir Ther. 2007. PMID: 17668565

5

HIV type-1 transmission dynamics in recent seroconverters: relationship with transmission of drug resistance and viral diversity.

Recordon-Pinson P, Anies G, Bruyand M, Neau D, Morlat P, Pellegrin JL, Groppi A, Thiébaut R, Dabis F, Fleury H, Masquelier B; ANRS CO3 Aquitaine Cohort. Recordon-Pinson P, et al. Among authors: fleury h. Antivir Ther. 2009;14(4):551-6. Antivir Ther. 2009. PMID: 19578240

6

Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.

Masquelier B, Pellegrin I, Ruffault A, Ragnaud JM, Morlat P, Michelet C, Doignon F, Biteau N, Fleury HJ. Masquelier B, et al. Among authors: fleury hj. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):330-4. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7533640

7

Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA.

Masquelier B, Neau D, Chêne G, Larbère J, Birac V, Ragnaud JM, Fleury HJ. Masquelier B, et al. Among authors: fleury hj. J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):309-12. doi: 10.1097/00126334-200112010-00001. J Acquir Immune Defic Syndr. 2001. PMID: 11707665 Clinical Trial.

8

Clonal analysis of HIV-1 variants in proviral DNA during treatment interruption in patients with multiple therapy failures.

Boucher S, Recordon-Pinson P, Neau D, Ragnaud JM, Titier K, Faure M, Fleury H, Masquelier B. Boucher S, et al. Among authors: fleury h. J Clin Virol. 2005 Dec;34(4):288-94. doi: 10.1016/j.jcv.2005.01.005. J Clin Virol. 2005. PMID: 16286052

9

An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients.

Capdepont S, Aurillac-Lavignolle V, Faure M, Dupon M, Morlat P, Ragnaud JM, Chêne G, Fleury H, Masquelier B; GECSA. Capdepont S, et al. Among authors: fleury h. J Clin Virol. 2006 May;36(1):36-42. doi: 10.1016/j.jcv.2006.01.008. Epub 2006 Feb 28. J Clin Virol. 2006. PMID: 16513416

10

Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.

Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H. Masquelier B, et al. Among authors: fleury h. Antivir Ther. 2006;11(6):827-30. Antivir Ther. 2006. PMID: 17310827 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

390 results

Search Page